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Abstract
Background In accordance with European Society of Parenteral and Enteral Nutrition guidelines, the combination of malnu-
trition universal screening tool (MUST), systemic inflammation [modified Glasgow prognostic score (mGPS)] and body compo-
sition [skeletal muscle index (SMI) and skeletal muscle density (SMD)] were examined in relation to clinical outcomes in
patients undergoing surgery for colorectal cancer (CRC).
Methods Data were collected for stages I–III CRC patients from prospectively maintained data base at the academic depart-
ment of surgery, Glasgow Royal Infirmary. From the initial sample of 1046, pre-admission MUST score was available in 984 pa-
tients. The classification into low malnutrition risk (MUST = 0, n = 810) and moderate to high malnutrition risk (MUST 1 to ≥2,
n = 174) groups and their relationship to systemic inflammatory response and body composition (SMI and SMD) with clinical
outcomes were examined using univariate and multivariate analyses.
Results Compared with those patients at low nutrition risk (MUST = 0), patients at moderate to high malnutrition risk (MUST
1 to ≥2) had an elevated mGPS (P < 0.001), neutrophil lymphocyte ratio (NLR) (P < 0.001), low SMI (P ≤ 0.001) and low SMD
(P = 0.015). MUST was an important prognostic factor for length of hospital stay (P < 0.001) and 3 years overall survival
(P < 0.001).
In low malnutrition risk patients (MUST = 0), those who were systemically inflammed (mGPS 1/2, n = 187), had an elevated NLR
(P < 0.001), low SMI (P < 0.001), low SMD (P < 0.01), increased post-operative complications (P < 0.05), longer hospital stay
>7 days (P < 0.001), and poorer 3 years survival (P < 0.05) compared with those who were not systemically inflamed. On mul-
tivariate analysis, American Society of Anaesthesiologist (ASA) score (P < 0.05) and mGPS (P < 0.05) were independently asso-
ciated with increased risk of clinical complications. ASA, mGPS, and NLR were independently associated with prolonged hospital
stay (P < 0.05, P < 0.05, and P < 0.001, respectively). ASA, tumour, node, metastasis stage, and mGPS were independently as-
sociated with overall survival (P < 0.01, P < 0.001, and P < 0.05, respectively).
In medium-risk to high-risk patients (MUST = 1/2), those who were systemically inflamed (mGPS 1/2, n = 75) had higher ASA
(P < 0.05), elevated NLR (P < 0.01), low SMI (P = 0.05) and low SMD (P < 0.05), increased length of hospital stay (P < 0.05), and
poorer 3 years survival (P < 0.01), compared with those who were not systemically inflamed.
Conlusions A small proportion of patients with primary operable CRC was at nutrition risk as defined by MUST alone in both
low risk nutrition patients and medium/high risk nutrition patients. The systemic inflammatory response was associated with
lower SMI, lower SMD, and poor clinical outcomes. The systemic inflammatory response is an important measure in the nutri-
tional assessment of patients undergoing surgery for CRC.
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Introduction
Cancer is a leading cause of death worldwide. Colorectal can-
cer (CRC) is the third most common cancer and is the fourth
leading cause of cancer related deaths worldwide. Incidence
of CRC is expected to increase by 60% to more than 2.2million
new cases and 1.1 million deaths by 2030.1 In the UK, CRC is
the common cancer with around 42, 000 new cases diagnosed
annually and is the second most common cause of cancer
death.2 Despite improvements in tumour staging and use of
the multidisciplinary team based approach, post-operative
complications and mortality persist, leading to poorer survival.
Therefore, staging the tumour and staging the host are impor-
tant steps in moving forward in the treatment of CRC.3
Malnutrition plays an important role in patients undergoing
surgery for CRC. Various nutritional assessment methods are
routinely used and, in the UK, malnutrition universal screen-
ing tool (MUST) has been adopted by the British Association
of Parenteral and Enteral Nutrition.4 MUST score is a
five-step process to categorize patients in low, medium, and
high nutritional risk groups as shown in Figure 1 and in accor-
dance with international nutritional guidelines.5 MUST score
is widely used in National Health Service in the UK, and nurs-
ing and medical staff are familiar with its use and is included
in the admission checklist. Its use in patients with cancer
has been validated.6
Systemic inflammation measured by modified Glasgow prog-
nostic score (mGPS) and neutrophil lymphocyte ratio (NLR)
have been shown to have prognostic value in patients under-
going surgery for CRC.7 Recently, in a cohort of 363 patients
undergoing surgery for CRC, it was reported that MUST was
directly associated with mGPS and NLR and a low skeletal
muscle index (SMI) measured using computed tomography
(CT).8 However, it was of interest that approximately 80% of
patients were at low nutritional risk, as defined by MUST,
and in these patients, approximately 20% were systemically
inflamed, and approximately 45% had a low SMI. Given that
systemic inflammation and low SMI are directly related,9 it
was of interest to examine their relationship and prognostic
value in patients at low and medium to high nutrition risk.
The aim of the present study was to examine the relationship
between malnutrition, systemic inflammation, body composi-
tion, and clinical outcomes in patients with operable CRC at
low and medium to high nutritional risk.
Figure 1 The malnutrition universal screening tool (MUST).4 BMI, body mass index.
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Patients and methods
Patients
Data were collected from prospectively maintained CRC data
base at the academic department of surgery, Glasgow Royal
Infirmary from March 2008 to March 2018. The flow diagram
of included patients is shown in Figure 2. From an initial sam-
ple of 1060 patients, patients with stage IV disease and
non-CRCs were excluded giving 1002 with stages I to III oper-
able CRC patients. 984 patients had MUST scores available in
this cohort, and these patients were entered into the study.
Methods
MUST score was calculated from pre-treatment admission re-
cord, and the relationship between MUST, clinico-pathological
characteristics, systemic inflammation, body composition, and
clinical outcomes in patients with primary operable CRC is
shown in Table 1. Systemic inflammation was measured using
mGPS and NLR. Pre-operative mGPS and NLR were analysed
from serum samples performed prior to surgery.
Body composition was assessed from the staging CT scan, and
L3 DICOM images were retrieved from picture archiving and
communication system (PACS). Body composition was
analysed using image J software (https://imagej.nih.gov/ij/)
by applying validated thresholds for CRC patients.10–12
Established thresholds of 29 to 150 Hounsfield unit (HU)
for skeletal muscle and 190 to 30 HU for adipose tissue
as previously described.13
The CT scans were analysed for total fat area (TFA), visceral
fat area (VFA), subcutaneous fat area (SFA), skeletal muscle
area (SMA), and skeletal muscle density (SMD). Measure-
ments were performed by two individuals (TA and RD) on a
sample of 40 patients. The interrater reliability was assessed
using interclass correlation coefficients (ICCs). The ICC values
were as follows: TFA and VFA = 0.999; SMA = 0.996 and
SMD = 0.993. The cross-sectional area of fat and muscles
was normalized for height squared (m2) to calculate fat and
skeletal muscle indices.
Subcutaneous adiposity was defined as SFI >50 cm2/m2 in
male patients and >42 cm2/m2 in female patients.10 Visceral
Figure 2 Flow diagram of included patients with operable colorectal cancer. MUST, malnutrition universal screening tool.
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obesity was defined as VFA > 160 cm2 in male patients and
>80cm2 in female patients.11 Sarcopenia (low SMI) was de-
fined per Martin threshold as SMI < 43 cm2/m2 in
BMI < 25 kg/m2and SMI < 53 cm2/m2 in BMI ≥ 25 kg/m2 in
male patients and SMI < 41 cm2/m2 in BMI < 25 kg/m2 and
SMI < 41 cm2/m2 with BMI ≥ 25 kg/m2 in female patients.
Myosteatosis (low SMD) was defined as SMD < 41 HU in pa-
tients with BMI < 25 kg/m2 and SMD < 33HU in patients with
BMI ≥ 25 kg/m2.12
Statistical analysis
χ2 test were used in the analysis of categorical variables. Lo-
gistic regression analysis was used to calculate odds ratio
(OR) and 95% confidence intervals (CIs) for post-operative
complications and length of hospital stay while cox propor-
tional hazard model was used to calculate hazard ratio (HR)
and 95% CI for overall survival. The Kaplan–Meier method
and log rank test were used for survival analysis. P value of
<0.05 was considered significant.
The enrolled patients were followed up until death or 1 Octo-
ber 2019 whichever came first. Median duration of follow up
was 52 months; three patients were lost to follow up.
Post-operative complications within a month of surgery with
Table 1 The relationship between MUST, clinico-pathological characteris-
tics, systemic inflammation, body composition, and clinical outcomes in
patients with primary operable colorectal cancer
Total
n = 984
MUST = 0
n = 810
(82.3%)
MUST 1 to ≥2
n = 174
(17.7%) P value
Clinico-pathological
Age (years) <0.001
<65 342 (34.8) 298 (36.8) 44 (25.3)
65–74 362 (36.8) 309 (38.1) 53 (30.1)
>74 280 (28.5) 203 (25.1) 77 (44.3)
Sex 0.017
Male 544 (55.3) 462 (57) 82 (47.1)
Female 440 (44.7) 348 (43) 92 (52.9)
ASA 0.005
I 193 (19.6) 167 (20.6) 26 (14.9)
II 450 (45.7) 374 (46.1) 76 (43.7)
III 308 (31.3) 248 (30.6) 60 (34.5)
IV 33 (3.4) 21 (2.6) 12 (6.9)
Presentation <0.001
Elective 922 (93.7) 770 (95.1) 152 (87.4)
Emergency 62 (6.3) 40 (4.9) 22 (12.6)
TNM 0.140
1 235 (23.9) 204 (25.2) 31 (17.8)
2 398 (40.4) 320 (39.5) 78 (44.8)
3 351 (35.7) 286 (35.3) 65 (37.4)
Primary cancer 0.006
Colon 588 (59.8) 468 (57.8) 120 (69)
Rectum 396 (40.2) 342 (42.2) 54 (31)
Adjuvant
treatment
0.245
No 464 (47.2) 375 (46.3) 89 (51.1)
Yes 520 (52.8) 435 (53.7) 85 (48.9)
Systemic
inflammation
mGPS <0.001
0 722 (73.4) 623 (76.9) 99 (56.9)
1 107 (10.9) 93 (11.5) 14 (8)
2 155 (15.8) 94 (11.6) 61 (35.1)
NLR <0.001
<3 515 (52.3) 451 (55.7) 64 (36.8)
3–5 303 (30.8) 236 (29.1) 67 (38.5)
>5 166 (16.9) 123 (15.2) 43 (24.7)
Body composition
Subcutaneous
adiposity (Ebadi
threshold)10
<0.001
No 197 (20) 122 (15.1) 75 (43.1)
Yes 787 (80) 688 (84.9) 99 (56.9)
Visceral obesity
(Doyle
threshold)11
<0.001
No 267 (27.1) 171 (21.1) 96 (55.2)
Yes 717 (72.9) 639 (78.9) 78 (44.8)
Low SMI
(Martin
threshold)12
<0.001
No 491 (49.9) 433 (53.5) 58 (33.3)
Yes 493 (50.1) 377 (46.5) 116 (66.7)
Low SMD
(Martin
threshold)12
0.015
No 326 (33.1) 282 (34.8) 44 (25.3)
Yes
658 (66.9) 528 (65.2) 130 (74.7)
Postoperative
outcome
(Continues)
Table 1 (continued)
Total
n = 984
MUST = 0
n = 810
(82.3%)
MUST 1 to ≥2
n = 174
(17.7%) P value
Any
complications
0.410
No 604 (61.4) 502 (62) 102 (58.6)
Yes 380 (38.6) 308 (38) 72 (41.4)
Infective
complication
0.500
No 738 (75) 611 (75.4) 127 (73)
Yes 246 (25) 199 (24.6) 47 (27)
Clavien–Dindo
grade
0.145
0 604 (61.4) 502 (62) 102 (58.6)
1–2 288 (29.3) 239 (29.5) 49 (28.2)
3–5 92 (9.3) 69 (8.5) 23 (13.2)
Length of
hospital stay
(days)
<0.001
≤7 448 (45.5) 394 (48.6) 54 (31)
>7 536 (54.5) 416 (51.4) 120 (69)
Survival <0.001
3 year survival
% (SE)
85 (1) 90 (1) 67 (4)
ASA, American Society of Anaesthesiologists; mGPS, modified Glas-
gow prognostic score; MUST, malnutrition universal screening tool;
NLR, neutrophil lymphocyte ratio; SE, standard error; SMD, skeletal
muscle density; SMI, skeletal muscle index; TNM, tumour, node,
and metastasis.
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their relationship to MUST were evaluated. Hospital stay was
divided into ≤7 days and >7 days as most of the patients un-
dergoing CRC will be discharged by days 4 to 5. Overall sur-
vival was defined as time in months from date of surgery to
time of death from any cause or time to the end of study
or loss to follow up. Patients were followed up as per CRC
guidelines with tumour markers check every 3 months, CT
follow up every 6 months and colonoscopy at 3 and 5 years
post operatively for first 5 years. Of the 131 patients who
died in this sample of 810 low nutritional risk patients, 115
died of CRC (16 other causes). All of the statistical analysis
was performed using SPSS version 25 (IBM Corporation,
2017, Armonk, NY).
Results
In 1002 patients with stages I to III CRC, 984 had MUST scores
available. Eight hundred ten patients (82%) were at low nutri-
tional risk (MUST = 0), 174 patients (18%) were at medium to
high nutritional risk (MUST 1 to ≥2). Mean age of patients was
68 years (range, 23–93). Fifty-five percent of patients were
male (n = 544). The relationship between MUST and
clinico-pathological factors is shown in Table 1. Compared with
low MUST, moderate to high MUST was associated with older
age (P < 0.001), female sex (P < 0.05), higher ASA (P < 0.01),
emergency presentation (P < 0.001), colon cancer (P < 0.01),
higher mGPS (P < 0.001) and NLR (P < 0.001), lower subcutane-
ous and visceral obesity (both P < 0.001), low SMI (P < 0.001),
low SMD (P < 0.05), longer hospital stay (P < 0.001) and poorer
3 year survival (P < 0.001).
In those patients at low nutrition risk (n = 810, 82%), the
relationship between mGPS and clinico-pathological factors
is shown in Table 2a. Compared with mGPS 0, mGPS 1/2
was associated with higher ASA (P < 0.01), higher NLR
(P < 0.001), low SMI (P < 0.001),, low SMD (P < 0.01), greater
length of hospital stay (P < 0.001), and poorer 3 year survival
(P < 0.05).
In those patients at medium to high nutritional risk (n = 174,
18%), the relationship between mGPS and clinico-pathological
factors are shown in Table 2b. Compared with mGPS 0, mGPS
1/2 was associated with higher ASA (P < 0.05), higher NLR
(P < 0.01), low SMI (P = 0.05), low SMD (P < 0.05), longer hos-
pital stay (P < 0.05), and poorer 3 years survival (P < 0.05).
The variables associated with post-operative complications in
patients with operable CRC in low-risk MUST (MUST = 0) are
presented in Table 3. On univariate logistic regression, age
(P = 0.014), sex (P = 0.052), ASA (P = 0.014), mGPS
(P = 0.018), and NLR (P = 0.083) were significantly associated
with post-operative complications. On multivariate analysis,
age (OR 1.22; 95% CI: 1.02–1.48; P = 0.034), ASA (OR 1.22;
95% CI: 1.01–1.47; P = 0.035), and mGPS (OR 1.25; 95% CI:
Table 2a The relationship between clinico-pathological characteristics,
systemic inflammation, body composition, and clinical outcomes in pa-
tients with primary operable colorectal cancer at low nutritional risk pa-
tients (MUST = 0)
Total
n = 810
(MUST = 0)
with
mGPS = 0
n = 623
(76.9%)
(MUST = 0)
with
mGPS = 1/2
n = 187
(23.1%)
P value
Clinico-pathological
Age (years) 0.166
<65 298 (36.8) 234 (37.6) 64 (34.2)
65–74 309 (38.1) 241 (38.7) 68 (36.4)
>74 203 (25.1) 148 (23.8) 55 (29.4)
Sex 0.821
Male 462 (57) 354 (56.8) 108 (57.8)
Female 348 (43) 269 (43.2) 79 (42.2)
ASA 0.004
I 167 (20.6) 134 (21.5) 33 (17.6)
II 374 (46.1) 298 (47.8) 76 (40.6)
III 248 (30.6) 180 (28.9) 68 (36.4)
IV 21 (2.6) 11 (1.8) 10 (5.3)
Presentation 0.148
Elective 770 (95.1) 596 (95.7) 174 (93)
Emergency 40 (4.9) 27 (4.3) 13 (7)
TNM 0.013
1 204 (25.2) 181 (29.1) 23 (12.3)
2 320 (39.5) 221 (35.5) 99 (52.9)
3 286 (35.3) 221 (35.5) 65 (34.8)
Primary cancer <0.001
Colon 468 (57.8) 332 (53.3) 136 (72.7)
Rectum 342 (42.2) 291 (46.7) 51 (27.3)
Adjuvant
treatment
0.667
No 375 (46.3) 291 (46.7) 84 (44.9)
Yes 435 (53.7) 332 (53.3) 103 (55.1)
Systemic inflammation
NLR <0.001
<3 451 (55.7) 376 (60.4) 75 (40.1)
3–5 236 (29.1) 176 (28.3) 60 (32.1)
>5 123 (15.2) 71 (11.4) 52 (27.8)
Body composition
Subcutaneous
adiposity (Ebadi
threshold)10
0.669
No 122 (15.1) 92 (14.8) 30 (16)
Yes 688 (84.9) 531 (85.2) 157 (84)
Visceral obesity
(Doyle
threshold)11
0.915
No 171 (21.1) 131 (21) 40 (21.4)
Yes 639 (78.9) 492 (79) 147 (78.6)
Low SMI (Martin
threshold)12
<0.001
No 434 (53.5) 355 (57) 78 (41.7)
Yes 377 (46.5) 268 (43) 109 (58.3)
Low SMD (Martin
threshold)12
0.003
No 282 (34.8) 234 (37.6) 48 (25.7)
Yes 528 (65.2) 389 (62.4) 139 (74.3)
Clinical outcomes
Any complications 0.030
No 501 (62) 398 (64) 103 (55.1)
Yes 309 (38) 225 (36) 84 (44.9)
Infective
complication
0.187
No 610 (75.3) 476 (76.4) 134 (71.7)
(Continues)
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1.01–1.54; P = 0.037) were independently associated with
post-operative complications.
The variables associated with length of hospital stay in pa-
tients with operable CRC in low-risk MUST (MUST = 0) are
presented in Table 4. On univariate logistic regression analy-
sis, age (P = 0.001), ASA (P < 0.001), tumour, node, metastasis
(TNM) stage (P = 0.019), mGPS (P < 0.001), NLR (P < 0.001),
and low SMI (P = 0.010) were significantly associated with
prolonged hospital stay >7 days. On multivariate analysis,
ASA (OR 1.28; 95% CI: 1.05–1.56; P = 0.014), mGPS (OR
1.30; 95% CI: 1.04–1.63; P = 0.022), and NLR (OR 1.65; 95%
CI: 1.35–2.03; P < 0.001) were independently associated with
prolonged hospital stay >7 days.
The variables associated with overall survival in patients with
operable CRC in low-risk MUST (MUST = 0) are shown in
Table 5. A total of 679 patients (84%) were alive at censor
date in MUST = 0 group. Death due to any cause occurred
in 131 (16%) patients. The median survival was 58 months
(range 0–139 months). After exclusion of 30 days mortality,
six patients (0.7%), there was significant association between
MUST score and overall survival (P < 0.001).
On univariate Cox regression survival analysis, age (P < 0.001),
sex (P = 0.021), ASA (P < 0.001), TNM stage (P < 0.001), mGPS
(P = 0.003), NLR (P = 0.023), low SMI (P = 0.076), and low SMD
(P = 0.005) were significantly associated with overall survival.
On multivariate analysis, age (HR 1.41; 95% CI: 1.21–1.79;
P = 0.004), sex (HR 1.49;95% CI: 1.04–2.15;p = 0.031), ASA
(HR 1.44; 95% CI:1.13–1.83; p = 0.003), TNM stage (HR 1.80;
95% CI:1.40–2.31; p < 0.001), mGPS (HR 1.29; 95% CI: 1.03–
1.62; p = 0.026) were independently associated with overall
survival.
Table 2a (continued)
Total
n = 810
(MUST = 0)
with
mGPS = 0
n = 623
(76.9%)
(MUST = 0)
with
mGPS = 1/2
n = 187
(23.1%)
P value
Yes 200 (24.7) 147 (23.6) 53 (28.3)
Clavien–Dindo
grade
0.058
0 501 (61.9) 398 (63.9) 103 (55.1)
1–2 240 (29.6) 174 (27.9) 66 (35.3)
3–5 69 (8.5) 51 (8.2) 18 (9.6)
Length of hospital
stay (days)
<0.001
≤7 394 (48.6) 324 (52) 70 (37.4)
>7 416 (51.4) 299 (48) 117 (62.6)
Survival 0.048
3 year survival %
(SE)
90% (1) 91% (1) 87% (3)
ASA, American Society of Anaesthesiologists score; mGPS, modi-
fied Glasgow prognostic score; MUST, malnutrition universal
screening tool; NLR, neutrophil lymphocyte ratio; SMD, skeletal
muscle density; SMI, skeletal muscle index; TNM, tumour, node,
and metastasis.
Table 2b The relationship between clinico-pathological characteristics,
systemic inflammation, body composition, and clinical outcomes in pa-
tients with primary operable colorectal cancer at medium to high risk of
malnutrition (MUST 1 to ≥2)
Total
n = 174
MUST 1 to
≥2 with
mGPS = 0
n = 99
(56.9%)
MUST 1 to
≥2 with
mGPS = 1/2
n = 75
(43.1%)
P
value
Clinico-pathological
Age (years) 0.676
<65 44 (25.3) 24 (24.2) 20 (26.7)
65–74 53 (30.5) 30 (30.3) 23 (30.7)
>74 77 (44.3) 45 (45.5) 32 (42.7)
Sex 0.155
Male 82 (47.1) 42 (42.4) 40 (53.3)
Female 92 (52.9) 57 (57.6) 35 (46.7)
ASA 0.024
I 26 (14.9) 22 (22.2) 4 (5.3)
II 76 (43.7) 40 (40.4) 36 (48)
III 60 (34.5) 31 (31.3) 29 (38.7)
IV 12 (6.9) 6 (6.1) 6 (8)
Presentation 0.248
Elective 152 (87.4) 89 (89.9) 63 (84)
Emergency 22 (12.6) 10 (10.1) 12 (16)
TNM 0.075
1 31 (17.8) 26 (26.3) 5 (6.7)
2 78 (44.8) 36 (36.4) 42 (56)
3 65 (37.4) 37 (37.4) 28 (37.3)
Primary cancer 0.002
Colon 120 (69) 59 (59.6) 61 (81.3)
Rectum 54 (31) 40 (40.4) 14 (18.7)
Adjuvant treatment 0.102
No 89 (51.1) 56 (56.6) 33 (44)
Yes 85 (48.9) 43 (43.4) 42 (56)
Systemic
inflammation
NLR 0.006
<3 64 (36.8) 45 (45.5) 19 (25.3)
3–5 67 (38.5) 35 (35.4) 32 (42.7)
>5 43 (24.7) 19 (19.2) 24 (32)
Body composition
Subcutaneous
adiposity (Ebadi
threshold)10
0.473
No 75 (43.1) 45 (45.5) 30 (40)
Yes 99 (56.9) 54 (54.5) 45 (60)
Visceral obesity
(Doyle threshold)11
0.300
No 96 (55.2) 58 (58.6) 38 (50.7)
Yes 78 (44.8) 41 (41.4) 37 (49.3)
Low SMI (Martin
threshold)12
0.052
No 58 (33.3) 39 (39.4) 19 (25.3)
Yes 116 (66.7) 60 (60.6) 56 (74.7)
Low SMD (Martin
threshold)12
0.036
No 44 (25.3) 31 (31.3) 13 (17.3)
Yes 130 (74.7) 68 (68.7) 62 (82.7)
Postoperative
outcome
Any complications 0.358
No 102 (58.6) 61 (61.6) 41 (54.7)
Yes 72 (41.4) 38 (38.4) 34 (45.3)
Infective
complication
0.003
No 127 (73) 81 (81.8) 46 (61.3)
(Continues)
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Discussion
The results of the present study in almost 1000 patients with
primary operable CRC show that approximately 80% of pa-
tients was at low nutritional risk. In those patients, at low nu-
trition risk (MUST 0), the systemic inflammatory response, as
evidenced by an elevated mGPS 1/2, was associated with low
SMI, greater length of hospital stay, and poorer overall sur-
vival. Similarly, in those patients at moderate/high nutritional
risk (MUST 1/2), an elevated mGPS was associated with low
SMI, greater length of hospital stay, and poorer overall sur-
vival. Therefore, the combined assessment of MUST and
mGPS has complementary value and may form the basis of
a routine disease-related malnutrition assessment in patients
with primary operable CRC.
The MUST tool is simple to use and provides recommendation
for healthcare professionals to improve nutritional status of
patients. MUST has been validated in terms of predicting clin-
ical outcomes and compares favourably with other nutritional
risk assessments.14,15 Similarly, the mGPS is simple and
objective to use, has been extensively validated in predicting
clinical outcomes, and compares favourably with other sys-
temic inflammation-based prognostic scores.7,16 Therefore,
the combined use in cancer patients undergoing nutritional
assessment is worthy of further study.
The results of the present study are consistent with the rec-
ommendations of a recent task force commissioned by four
major international clinical nutrition societies: European
Society of Parenteral and Enteral Nutrition (ESPEN), American
Society of Parenteral and Enteral Nutrition (ASPEN), Paren-
teral and Enteral Nutrition Society of Asia (PENSA) and Latin
American Federation for Parenteral and Enteral Nutrition
(FELANPE). They proposed that the diagnosis of malnutrition
was based on three phenotypic criteria (unintentional weight
loss, low body mass index, and low muscle mass) and two
etiologic criteria (low food intake or low food assimilation
and inflammation or disease burden) and that to diagnose
malnutrition at least one phenotypic and one etiologic
criteria should be present. Therefore, when malnutrition is
caused by an underlying chronic disease, it may be termed
disease-related malnutrition and in the presence of a sys-
temic inflammatory response may be considered to be
cachexia.17
In the present study of patients with operable CRC, there was
no direct measure of physical function made and so we were
Table 2b (continued)
Total
n = 174
MUST 1 to
≥2 with
mGPS = 0
n = 99
(56.9%)
MUST 1 to
≥2 with
mGPS = 1/2
n = 75
(43.1%)
P
value
Yes 47 (27) 18 (18.2) 29 (38.7)
Clavien–Dindo grade 0.515
0 102 (58.6) 61 (61.6) 41 (54.7)
1–2 49 (28.2) 25 (25.3) 24 (32)
3–5 23 (13.2) 13 (13.1) 10 (13.3)
Length of hospital
stay (days)
0.038
≤7 54 (31) 37 (37.4) 17 (22.7)
>7 120 (69) 62 (62.6) 58 (77.3)
Survival 0.003
3 year survival %
(SE)
67 (4) 73 (5) 58 (6)
ASA, American Society of Anaesthesiologists score; mGPS, modi-
fied Glasgow prognostic score; MUST, malnutrition universal
screening tool; NLR, neutrophil lymphocyte ratio; SMD, skeletal
muscle density; SMI, skeletal muscle index; TNM, tumour, node,
and metastasis.
Table 3 The relationship between clinico-pathological characteristics, systemic inflammation, body composition and any post-operative complications
patients with primary operable colorectal cancer, at low risk MUST (MUST = 0)
Variables Univariate analysis P value Multivariate analysis P value
OR (95% CI) OR (95% CI)
Clinico-pathological
Age (<65/65–74/>74) 1.27 (1.05–1.52) 0.014 1.22 (1.02–1.48) 0.034
Sex (Male/Female) 1.33 (1.00–1.78) 0.052 1.31 (0.98–1.74) 0.073
ASA (I-IV) 1.26 (1.05–1.52) 0.014 1.22 (1.01–1.47) 0.035
TNM stage (I–III) 1.08 (0.90–1.30) 0.408 — —
Systemic inflammation
mGPS (0/1/2) 1.28 (1.04–1.57) 0.018 1.25 (1.01–1.54) 0.037
NLR (<3/3–5/>5) 1.18 (0.98–1.43) 0.083 0.303
Body Composition
Subcutaneous adiposity (Ebadi threshold)10 1.15 (0.77–1.72) 0.493 — —
Visceral adiposity (Doyle threshold)11 1.14 (0.80–1.61) 0.476 — —
Low SMI (Martin threshold)12 1.10 (0.83–1.47) 0.500 — —
Low SMD (Martin threshold)12 1.08 (0.80–1.45) 0.624 — —
Binary logistic regression variables with P < 0.1 on univariate analysis were entered into backward conditional multivariate analysis. P
value <0.05 was considered significant. ASA, American Society of Anaesthesiologists; CI, confidence interval; mGPS, modified Glasgow
prognostic score; NLR, neutrophil lymphocyte ratio; OR, odds ratio; SMD, skeletal muscle radiodensity; SMI, skeletal muscle index; TNM,
tumour, node, metastasis.
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unable to explore the relationship between the systemic in-
flammatory response and physical activity in these patients.
However, in a recent publication, the relationship between
the mGPS and measures of physical activity was examined
in patients with advanced lung cancer.18 This study showed
that an elevated mGPS was significantly and independently
associated with poorer handgrip strength. Therefore, there
is some evidence that the presence of the systemic inflamma-
tory response is associated with a poor capacity for activity in
patients with cancer.
The strengths of the present study include a large sample
size and detailed phenotypic characterization of patients with
primary operable CRC. However, there are a number of
limitations. The present study is from a single institution and
therefore may not be representative of all patients with
primary operable CRC. Also, the MUST-defined cohort of
moderate/high risk patients was relatively small. Therefore,
confirmatory studies are required. However, given the sim-
plicity of our study approach, it is likely that this work will
be readily repeated.
It will be interesting to longitudinally study this relationship
between MUST, systemic inflammation, and body composi-
tion in CRC cohort. Improving fitness of patient by addressing
malnutrition with muscle mass and function coupled with de-
crease in stress of surgery (inflammatory response) will help
in reducing adverse post-operative outcome and achieve the
best possible outcome for patient. Reducing catabolism and
improving anabolic response by addressing nutrition, inflam-
mation, muscle mass, and function are important compo-
nents in treatment of patients with CRC.
Table 4 The relationship between clinico-pathological characteristics, systemic inflammation, body composition, and length of hospital stay (≤7 or
>7 days) in patients with primary operable colorectal cancer, at low nutrition risk (MUST = 0)
Variables Univariate analysis P value Multivariate analysis P value
OR (95% CI) OR (95% CI)
Clinico-pathological
Age (<65/65–74/>74) 1.36 (1.14–1.63) 0.001 1.21 (1.00–1.47) 0.055
Sex (Male/Female) 1.12 (0.85–1.48) 0.416 — —
ASA (I–IV) 1.42 (1.19–1.71) <0.001 1.28 (1.05–1.56) 0.014
TNM stage (I–III) 1.24 (1.04–1.49) 0.019 1.19 (0.98–1.43) 0.074
Systemic inflammation
mGPS (0/1/2) 1.54 (1.24–1.91) <0.001 1.30 (1.04–1.63) 0.022
NLR (<3/3–5/>5) 1.78 (1.47–2.17) <0.001 1.65 (1.35–2.03) <0.001
Body composition
Subcutaneous adiposity (Ebadi threshold)10 1.03 (0.70–1.50) 0.897 — —
Visceral adiposity (Doyle threshold)11 1.15 (0.82–1.62) 0.406 — —
Low SMI (Martin threshold)12 1.44 (1.09–1.90) 0.010 — 0.200
Low SMD (Martin threshold)12 1.32 (0.99–1.77) 0.059 — 0.965
Binary logistic regression variables with P < 0.1 on univariate analysis were entered into backward conditional multivariate analysis. P
value <0.05 was considered significant. ASA, American Society of Anaesthesiologists; CI, confidence interval; mGPS, modified Glasgow
prognostic score; NLR, neutrophil lymphocyte ratio; OR, odds ratio; SMD, skeletal muscle radiodensity; SMI, skeletal muscle index; TNM,
tumour, node, metastasis.
Table 5 The relationship between clinico-pathological characteristics, systemic inflammation, body composition, and overall survival in patients with
primary operable colorectal cancer, at low nutritional risk (MUST = 0)
Variables Univariate analysis P value Multivariate analysis P value
HR (95% CI) HR (95% CI)
Clinico-pathological
Age (<65/65–74/>74) 1.59 (1.27–1.99) <0.001 1.41 (1.21–1.79) 0.004
Sex (Male/Female) 1.52 (1.06–2.18) 0.021 1.49 (1.04–2.15) 0.031
ASA (I–IV) 1.67 (1.33–2.09) <0.001 1.44 (1.13–1.83) 0.003
TNM stage (I–III) 1.80 (1.41–2.29) <0.001 1.80 (1.40–2.31) <0.001
Systemic inflammation
mGPS (0/1/2) 1.43 (1.15–1.79) 0.003 1.29 (1.03–1.62) 0.026
NLR (<3/3–5/>5) 1.30 (1.04–1.62) 0.023 0.275
Body composition
Subcutaneous adiposity (Ebadi threshold)10 0.85 (0.54–1.35) 0.505 - -
Visceral adiposity (Doyle threshold)11 1.05 (0.69–1.60) 0.821 - -
Low SMI (Martin threshold)12 1.36 (0.97–1.92) 0.076 0.859
Low SMD (Martin threshold)12 1.69 (1.15–2.48) 0.005 0.235
Cox regression analysis variables with P < 0.1 on univariate analysis were entered into backward conditional multivariate analysis. P value
<0.05 was considered significant. ASA, American Society of Anaesthesiologists; CI, confidence interval; HR, hazard ratio; mGPS, modified
Glasgow Prognostic Score; NLR, neutrophil lymphocyte ratio; SMD, skeletal muscle radiodensity; SMI, skeletal muscle index; TNM, tumour,
node, metastasis.
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Conclusions
The combination of MUST and mGPS would appear to provide
a reliable objective assessment tool for risk stratification of
length of hospital stay and survival in patients with primary
operable CRC.
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